

STATE PROCUREMENT OFFICE NOTICE OF REQUEST FOR EXEMPTION FROM HRS CHAPTER 103D

'14 MAR 13 P1:59

STATE PROCUREMENT OF FILE STATE OF HAWA!!

ТО:	Chief Procurement Officer
FROM:	HEALTH/SLD

Name of Requesting Department

Pursuant to HRS § 103D-102(b)(4) and HAR chapter 3-120, the Department requests a procurement exemption for the following:

	e goods, se ts & Westerr		n:	5 11		
 	1 0					

2. Vendor/Contractor/Service Provider: **Bio-Rad Laboratories** 3. Amount of Request: \$ 75,000

3/13/2014 ek 4/20 3/17/2015 64 6/20

3/10/2015 5. Prior SPO-007, Procurement Exemption (PE): 13-070K 4. Term of Contract From:

6. Explain in detail, why it is not practicable or not advantageous for the department to procure by competitive means:

State Laboratories' equipment, instrumentation, and software is proprietary to Bio-Rad Laboratories. No other products are USFDA approved to be used with this equipment. The tests to be purchased are USFDA approved for screening of human serum, plasma, and cadaveric serum for antibodies to Human Immundeficiency Virus (HIV) Types 1 (Groups M and 0) and/or 2 (HIV-1/HIV-2). These agents have been identified as the causative agents of Acquired Immunodeficiency Virus Syndrome (AIDS). This product, from Bio-Rad Labortories, who acquired Sanofi Diagnostics Pastuer, is marketed by their Genetic Systems Division, uses recombinant and synthetic peptide antigens. The use of this type of antigen is believed to yield accurate results, without a large number of false This product was validated for use by our laboratory in 2007 to screen oral fluid specimens as well as serum, plasma, and cadaveric serum for HIV-1/2 antibodies. It is not practicable or not advantageous for the department to procure by competitive means since our laboratory has already validated the 3rd generation Genetic Systems HIV-1/2 + O EIA test kit and is used to detect HIV antibodies and as contingency to the 4th generation ARCHITECT HIV Ag/Ab Combo Assay(see attached Page 3).

7. Explain in detail, the process that will be or was utilized in selecting the vendor/contractor/service provider:

Our laboratory uses two products for screening of patient specimens for the presence of HIV-1 and HIV-2 antibodies so there is already a fair and open competition. The State Laboratories Division uses the 4th generation ARCHITECT HIV Ag/Ab Combo Assay for HIV-1 /HIV-2 manufactured by Abbott Laboratories to do the initial screening on serum/plasma specimens for the detection of HIV p24 antigen and antibodies to HIV-1 (M and 0) and HIV-2 and was initially validated under S.S. No. 11-059-B. The SLD equipment and instrumentation is proprietary to Abbott Laboratories. No other products are USFDA approved to be used with this Our laboratory currently uses the 3rd generation Genetic Systems HIV-1/2 + O EIA test kits for screening serum and plasma specimens for the presence of HIV-1/2 antibodies. Our laboratory had validated the use of the 3rd generation Genetic Systems HIV-1/2 + O EIA test kit with oral fluid specimens. Our laboratory uses the 3rd generation Genetic Systems HIV-1/2 + O EIA test kit as contingency in the event the Abbott product is not available although we do not have the capability to detect HIV-1 antigen. Similarly, Bio-Rad's equipment and software is proprietary to Bio-Rad and is not USFDA approved to be used with any other products. Both manufacturer's HIV products are currently being used in our laboratory.

Name	Division/Agency	Phone Number		e-mail address	e =
ail Kunimoto	Health/SLD	453-6700	gail.k	unimoto@doh.hawaii.go	V
10 Seed				7 1	7 -
I certify that	pprovals and internal cont t the information provided artment Head Signature	-		true and correct.	ent.
1 12					
	For Chief Pr	ocurement Office		te Notice Posted: 3/	117/12
			- T	<u></u>	1''
	hall be directed to the contact			ion to this notice to iss	ue an ex
iiti att witiiii seven taienua	ir days or as otherwise allow	ved from date notice f	posted to:		
nti act within seven calenda	r days or as otherwise allow state.procurement.offic		oosted to:		
	state.procurement.offic		posted to:		
	state.procurement.offic		oosted to:		
Approval is base a contingency manufacturer to 3/13/14 to 3/14 required to be posted on the A	state.procurement.office PO) Comments: ed on the department's plan should Maxim phat produces USFDA Web. 2/15. HRS section 103 compliant on the Hawkward Reporting system.	representation that products become estern Blot Test Kit BD-310(c), and HA vaii Compliance Ex	et Bio-Rad Labora unavailable and s. Approval is g R section 3-122	d is the only oth ranted for the perion -112 shall apply (i. rd is required to b	er od .e.
Approval is base a contingency manufacturer to 3/13/14 to 3/1 required to be posted on the A	state.procurement.office PO) Comments: ed on the department's plan should Maxim phat produces USFDA Web. 2/15. HRS section 103 compliant on the Hawkward Reporting system.	representation that products become estern Blot Test Kit BD-310(c), and HA vaii Compliance Ex	ot Bio-Rad Labora unavailable and is. Approval is g R section 3-122 (press) and awa	d is the only oth ranted for the perion -112 shall apply (i. rd is required to b	er od e. oe
Approval is base a contingency manufacturer to 3/13/14 to 3/14 required to be posted on the A	state.procurement.office PO) Comments: ed on the department's plan should Maxim phat produces USFDA Web. 2/15. HRS section 103 compliant on the Hawkward Reporting system.	representation that products become estern Blot Test Kit BD-310(c), and HA vaii Compliance Ex	ot Bio-Rad Labora unavailable and is. Approval is g R section 3-122 (press) and awa	d is the only oth ranted for the perion -112 shall apply (i. rd is required to b	er od e. oe
Approval is base a contingency manufacturer to 3/13/14 to 3/14 required to be posted on the A	state.procurement.office PO) Comments: ed on the department's plan should Maxim phat produces USFDA Web. 2/15. HRS section 103 compliant on the Hawkward Reporting system.	representation that products become estern Blot Test Kit BD-310(c), and HA vaii Compliance Ex	ot Bio-Rad Labora unavailable and is. Approval is g R section 3-122 (press) and awa	d is the only oth ranted for the perion -112 shall apply (i. rd is required to b	er od e. oe
Approval is base a contingency manufacturer to 3/13/14 to 3/14 required to be posted on the A	state.procurement.office PO) Comments: ed on the department's plan should Maxim phat produces USFDA Web. 2/15. HRS section 103 compliant on the Hawkward Reporting system.	representation that products become estern Blot Test Kit BD-310(c), and HA vaii Compliance Ex	ot Bio-Rad Labora unavailable and is. Approval is g R section 3-122 (press) and awa	d is the only oth ranted for the perion -112 shall apply (i. rd is required to b	er od e. oe
Approval is base a contingency manufacturer to 3/13/14 to 3/1 required to be posted on the Alf there are kevin.s.takaesu	state.procurement.office 20) Comments: ed on the department's plan should Maxim plat produces USFDA Web. 2/15. HRS section 103 compliant on the Hawkward Reporting system. any questions, placeholder and pl	representation that products become estern Blot Test Kit BD-310(c), and HA vaii Compliance Ex	et Bio-Rad Labora unavailable and es. Approval is g R section 3-122 opress) and awa devin Takaesu	d is the only oth ranted for the perion -112 shall apply (i. rd is required to b	er od e. oe
Approval is base a contingency manufacturer to 3/13/14 to 3/14 required to be posted on the A	state.procurement.office PO) Comments: ed on the department's plan should Maxim phat produces USFDA Web. 2/15. HRS section 103 compliant on the Hawkward Reporting system.	representation that products become estern Blot Test Kit BD-310(c), and HA vaii Compliance Ex	et Bio-Rad Labora unavailable and es. Approval is g R section 3-122 opress) and awa devin Takaesu	d is the only oth ranted for the perion -112 shall apply (i. rd is required to b	er od e. oe
Approval is base a contingency manufacturer to 3/13/14 to 3/1 required to be posted on the Alf there are kevin.s.takaesu	state.procurement.office 20) Comments: ed on the department's plan should Maxim plat produces USFDA Web. 2/15. HRS section 103 compliant on the Hawkward Reporting system. any questions, placeholder and pl	representation that products become estern Blot Test Kit BD-310(c), and HA vaii Compliance Ex	et Bio-Rad Labora unavailable and es. Approval is g R section 3-122 opress) and awa devin Takaesu	d is the only oth ranted for the perion -112 shall apply (i. rd is required to b	er od e. oe

REQUEST FOR EXEMPTION FROM CHAPTER 103D Human Immunodeficiency Virus EIA Test Kits and Western Blot Test Kits March 4, 2014 Page 3

6. Explain in detail, why it is not practicable or not advantageous for the department to procure by competitive means: (continued)

by Abbott Laboratories uses chemiluminescent microparticle immunoassay (CMIA) technology (P.E. 14-017B).

In addition, there are currently only two USFDA approved supplementary or confirmatory tests by western blot for use on HIV-1 serum screen reactive specimens. The USFDA approved western blot test kits are the Cambridge Biotech HIV-1 Western Blot Test Kit manufactured and distributed by Maxim Biomedical, Inc. and the Bio-Rad HIV-1 Western Blot Test Kit. Procurement by competitive means for the Bio-Rad HIV-1 Western Blot Test Kit is not practicable or advantageous for the department to procure by competitive means because our laboratory already performs the Cambridge Biotech HIV-1 Western Blot Test as the primary supplementary/confirmatory test kit for HIV-1 antibody screen reactive specimens (P. E. 13-095K).

We are requesting to have the Bio-Rad HIV-1 Western Blot Test available for contingency use, as may be needed if the test of its only competitor, Cambridge Biotech HIV-1 Western Blot, becomes unavailable or has quality assurance issues.